AIO-Studien-gGmbH

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 2007-01-01

Employees: 11

Market Cap: -

Website: http://www.aio-studien-ggmbh.de

Clinical Trials

Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome

Recruiting

Conditions: Squamous Cell Carcinoma of the Hypopharynx
Squamous Cell Carcinoma of the Larynx
Squamous Cell Carcinoma of the Oropharynx
Squamous Cell Carcinoma of the Oral Cavity

First Posted Date: 2024-04-24

Last Posted Date: 2024-11-13

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 120

Registration Number: NCT06380686

Locations: 🇩🇪
Onkologie/Studienzentrum am Raschplatz GbR, Hannover, Germany
🇩🇪
Universitätsklinikum Essen, Essen, Germany

AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Other: Minimal documentation
Other: Extended documentation

First Posted Date: 2023-01-27

Last Posted Date: 2023-11-09

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 3000

Registration Number: NCT05701150

Locations: 🇩🇪
Praxis für interdisziplinäre Onkologie & Hämatologie, Freiburg, Baden-Württemberg, Germany
🇩🇪
Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Baden-Württemberg, Germany
🇩🇪
Klinikum der Universität München, München, Bayern, Germany

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer

Phase 2

Recruiting

Conditions: Colon Cancer
BRAF V600 Mutation
Localized Cancer
BRAF V600E
Colorectal Cancer

Interventions: Drug: Binimetinib

First Posted Date: 2022-08-22

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 48

Registration Number: NCT05510895

Locations: 🇩🇪
Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Germany

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2

Withdrawn

Conditions: NSCLC Stage IV

Interventions: Drug: combination regimen tremelimumab /durvalumab
Drug: platinum-based chemotherapy (SoC)

First Posted Date: 2022-05-19

Last Posted Date: 2022-09-27

Lead Sponsor: AIO-Studien-gGmbH

Registration Number: NCT05383001

Locations: 🇩🇪
Asklepios Fachkliniken München-Gauting, Gauting, Germany

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer

Phase 1

Recruiting

Conditions: Chemo-refractory Colorectal Carcinoma

First Posted Date: 2022-01-27

Last Posted Date: 2023-06-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 18

Registration Number: NCT05212012

Locations: 🇩🇪
Universitätsklinikum Hamburg Eppendorf - II. Med., Hamburg, Germany
🇩🇪
Universitätsklinikum Ulm - Innere Med. I, Ulm, Germany

Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma

Completed

Conditions: Solid Tumor
Malignant Lymphoma
Anemia, Iron Deficiency

First Posted Date: 2022-01-13

Last Posted Date: 2022-02-15

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 1053

Registration Number: NCT05190263

Locations: 🇩🇪
Studienzentrum Prof. Dr. med. Hartmut Link, Facharzt für Innere Medizin, Hämatologie und Internistische Onkologie, Kaiserslautern, Germany

Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Atezolizumab

First Posted Date: 2021-11-12

Last Posted Date: 2024-12-16

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 80

Registration Number: NCT05118724

Locations: 🇩🇪
Westdeutsches Tumorzentrum, Essen, Germany

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Phase 2

Recruiting

Conditions: NSCLC
EGFR Positive Non-small Cell Lung Cancer
Oligoprogression

Interventions: Drug: Osimertinib
Radiation: Radiotherapy

First Posted Date: 2021-10-22

Last Posted Date: 2024-07-26

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 40

Registration Number: NCT05089916

Locations: 🇩🇪
LMU Klinikum der Universität München, München, Germany

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Phase 2

Terminated

Conditions: Cholangiocarcinoma
Biliary Tract Cancer

Interventions: Drug: Bintrafusp alfa

First Posted Date: 2021-01-27

Last Posted Date: 2022-05-23

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 3

Registration Number: NCT04727541

Locations: 🇩🇪
Universitätsklinikum RWTH Aachen - Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Aachen, Germany
🇩🇪
Universitätsklinikum Frankfurt - Medizinische Klinik 1, Frankfurt, Germany

Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Phase 2

Active, not recruiting

Conditions: SCLC, Extensive Stage

Interventions: Drug: Atezolizumab

First Posted Date: 2020-01-09

Last Posted Date: 2024-07-26

Lead Sponsor: AIO-Studien-gGmbH

Target Recruit Count: 70

Registration Number: NCT04221529

Locations: 🇦🇹
Klinikum Klagenfurt, Klagenfurt, Austria
🇩🇪
St. Josef Hospital, Bochum, Germany
🇩🇪
Klinikum Esslingen GmbH, Esslingen, Germany

and more 16 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy